Search research articles
Contact Us
Filters
Showing results (231-240 of 293) with videos related to
Page
of 30
Sort By:
Biochemistry
|
April 19, 2006
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization
Orsolya Polgar, Csilla Ozvegy-Laczka, Robert W Robey, et al.
Cancer Research
|
November 10, 2011
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR
Chunxi Wang, Zhihui Liu, Chan-Wook Woo, et al.
Biochimica Et Biophysica Acta
|
May 2, 2009
Arginine 383 is a crucial residue in ABCG2 biogenesis
Orsolya Polgar, Lilangi S Ediriwickrema, Robert W Robey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2010
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
Wilfred D Stein, James L Gulley, Jeff Schlom, et al.
Oncotarget
|
September 17, 2016
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras
Julian C Bahr, Robert W Robey, Victoria Luchenko, et al.
Leukemia & Lymphoma
|
September 21, 2025
From dimensions through dynamics to outcomes - lymph nodes and skin assessments predict CTCL outcomes
Alexander Kaminsky, Lauren M Fahmy, Zaid Bilgrami, et al.
Ebiomedicine
|
August 24, 2024
Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses
Harshraj Leuva, Mengxi Zhou, Nader Jamaleddine, et al.
Cancers
|
July 29, 2025
Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment
Andrew V Kossenkov, Noor Dawany, Sonali Majumdar, et al.
Journal of Clinical Pharmacology
|
December 5, 2015
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation
Cody J Peer, Andrew K L Goey, Tristan M Sissung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2009
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
Sukyung Woo, Erin R Gardner, Xiaohong Chen, et al.
Page
of 30
Search research articles
Search
Showing results (231-240 of 293) with videos related to
Sort By:
Page
of 30
Biochemistry
|
April 19, 2006
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization
Orsolya Polgar, Csilla Ozvegy-Laczka, Robert W Robey, et al.
Cancer Research
|
November 10, 2011
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR
Chunxi Wang, Zhihui Liu, Chan-Wook Woo, et al.
Biochimica Et Biophysica Acta
|
May 2, 2009
Arginine 383 is a crucial residue in ABCG2 biogenesis
Orsolya Polgar, Lilangi S Ediriwickrema, Robert W Robey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2010
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
Wilfred D Stein, James L Gulley, Jeff Schlom, et al.
Oncotarget
|
September 17, 2016
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras
Julian C Bahr, Robert W Robey, Victoria Luchenko, et al.
Leukemia & Lymphoma
|
September 21, 2025
From dimensions through dynamics to outcomes - lymph nodes and skin assessments predict CTCL outcomes
Alexander Kaminsky, Lauren M Fahmy, Zaid Bilgrami, et al.
Ebiomedicine
|
August 24, 2024
Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses
Harshraj Leuva, Mengxi Zhou, Nader Jamaleddine, et al.
Cancers
|
July 29, 2025
Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment
Andrew V Kossenkov, Noor Dawany, Sonali Majumdar, et al.
Journal of Clinical Pharmacology
|
December 5, 2015
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation
Cody J Peer, Andrew K L Goey, Tristan M Sissung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2009
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
Sukyung Woo, Erin R Gardner, Xiaohong Chen, et al.
Page
of 30